Clinical trials: Myeloid
Chronic Myelogenous Leukemia
A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
Phase I clinical trial to explore the safety, tolerability, and initial efficacy of TQB3911 tablets in BCR::ABL fusion gene positive leukemia.
- Trial name
- NCT06672263
- Testing
- TQB3911 tablets
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
The purpose of this study was to determine the safety and tolerability of gilteritinib given in combination with atezolizumab in participants with relapsed or treatment refractory FMS-like tyrosine kinase 3 (FLT3) mutated AML and…
- Trial name
- NCT03730012
- Testing
- gilteritinib, atezolizumab
- Where
- 12 sites in United States
- Volunteers
- 11 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Chronic Myeloid Leukaemia
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
Chronic myeloid leukaemia (CML) diagnosis is based on the demonstration of a BCR-ABL fusion transcript expressed by the Philadelphia (Ph) chromosome by RQ-PCR and/or the demonstration of t(9;22)(q34;q11) by conventional…
- Trial name
- NCT05893836
- Where
- United Kingdom
- Volunteers
- 555 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
The purpose of this trial is to demonstrate benefit with respect to hematopoietic response in subjects with anemia of cancer randomized to Darbepoetin Alfa once every 4 weeks.
- Trial name
- NCT00095277
- Testing
- Darbepoetin Alfa
- Volunteers
- 220 people
- Sponsor
- Amgen
Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia
The purpose of this study is to determine the safety and effectiveness of INNO-406 in adult patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.
- Trial name
- NCT00352677
- Testing
- INNO-406
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 100 people
- Sponsor
- CytRx
Chronic Myelogenous Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
This study will evaluate MK0457 in combination with Dasatinib in patients with Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Efficacy and Safety will be evaluated.
- Trial name
- NCT00500006
- Testing
- MK0457, dasatinib
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard…
- Conditions
- Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult, Acute Myelogenous Leukemia
- Trial name
- NCT02267863
- Testing
- APTO-253
- Where
- 13 sites in United States
- Volunteers
- 21 people
- Sponsor
- Aptose Biosciences Inc.
Leukemia
Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study
This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days.
- Trial name
- PASS (NCT02546791)
- Testing
- Dasatinib
- Volunteers
- 101 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and…
- Trial name
- NCT04953897
- Testing
- ASTX727
- Where
- 21 sites in United States, Armenia and 6 more
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Acute Myeloid Leukemia, Relapsed AML
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML).
- Conditions
- Acute Myeloid Leukemia, Relapsed AML, Refractory AML
- Trial name
- NCT03516760
- Testing
- GEM333
- Where
- 7 sites in Germany
- Volunteers
- 36 people
- Sponsor
- AvenCell Europe GmbH
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT04988555
- Testing
- Enzomenib, azoles, Venetoclax
- Where
- 104 sites in United States, Belgium and 10 more
- Volunteers
- 606 people
- Sponsor
- Sumitomo Pharma America, Inc.
Acute Myeloid Leukemia
A Study of TAS1440 With ATRA in Subjects With r/r AML
This is a multicenter, 2-part, Phase 1 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of TAS1440 administered as a single agent and in combination with all-trans retinoic acid…
- Trial name
- NCT04282668
- Testing
- TAS1440, TAS1440 + ATRA
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Acute Myeloid Leukemia
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
This Phase 3 study assesses two drug regimens as the initial treatment of patients who are at least 70 years of age and have newly diagnosed acute myeloid leukemia (AML) for whom the doctor does not recommend the use of standard…
- Trial name
- SEAMLESS (NCT01303796)
- Testing
- Sapacitabine, Decitabine
- Where
- 118 sites in United States, Austria and 10 more
- Volunteers
- 482 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Acute Myeloid Leukemia
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to describe the dose limiting toxicities (DLT) and define the maximum tolerated dose (MTD) of ASP2215 when combined with cytarabine/idarubicin or daunorubicin remission induction in a 7+3 schedule.
- Trial name
- NCT02236013
- Testing
- Gilteritinib, Idarubicin, Cytarabine
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia (CMML)
SNS-301 Monotherapy in High Risk MDS and CMML
To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 in patients with ASPH+ high risk MDS and CMML.
- Trial name
- NCT04217720
- Testing
- SNS-301
- Sponsor
- Sensei Biotherapeutics, Inc.
Chronic Myelogenous Leukemia, CML Chronic Phase
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation.
- Conditions
- Chronic Myelogenous Leukemia, CML Chronic Phase, CML Accelerated Phase
- Trial name
- NCT06530810
- Testing
- HS-10382+Flumatinib
- Volunteers
- 100 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML).
- Trial name
- NCT04155580
- Testing
- ASTX660, ASTX727
- Where
- 15 sites in United States
- Volunteers
- 68 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or…
- Trial name
- NCT04477291
- Testing
- CG-806
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Aptose Biosciences Inc.
Leukemia, Myeloid, Acute
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Phase I Dose Escalation: Primary objective is to determine the Maximum Tolerated Dose (MTD) and the recommended dose for Phase I Extension.
- Trial name
- NCT02632721
- Testing
- Decitabine, BI 836858
- Where
- 14 sites in United States, Germany and 2 more
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.